Skip to main content
Premium Trial:

Request an Annual Quote

Getting By With a Little Help

Omeros, a Seattle-based drug discovery firm, is getting an injection of money from Washington State's Life Sciences Discovery Fund and local entrepreneur and billionaire Paul Allen, Xconomy reports. Omeros is trying to come up with therapeutics that bind G-protein coupled receptors — targets that have been deemed "undruggable" by many. "We see the Omeros GPCR technology as a major disruptive opportunity," says Steve Hall, who is the managing director of Allen's Vulcan Capital. Omeros is receiving $20 million from Vulcan and $5 million from the state fund. Under the terms of the deal, Xconomy says that both entities "will have skin in the game with Omeros" as they may receive a percentage of future profits and royalties.

HT: Fierce Biotech

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.